Skip to content

Gyre Therapeutics, Inc. GYRE Return on invested capital

Return on invested capital at other companies

Eli Lilly logo
Eli LillyLLY
42%+16.6pp
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
-46.7%-14.4pp
Viking Therapeutics logo
Viking TherapeuticsVKTX
-59.2%-292pp
Theravance Biopharma logo
Theravance BiopharmaTBPH
1.5%+0.8pp
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-0.1%-0.1pp
Opko Health logo
Opko HealthOPK
-7.7%-2.8pp

Other financials

Income statement

See full
Revenue$22.5M+2.1%
Gross profit$21.3M+0.6%
Operating income-$9.4M-512%
Net income-$8.7M-422%
EPS (diluted)-$0.10

Balance sheet

See full
Cash & equivalents$37.5M+149%
Total debt$823.0K-48.1%
Total equity$101.3M+48.7%
Total assets$162.0M+24.8%

Cash flow

See full
Operating cash flow$3.2M+2,565%
CapEx$178.0K+45.9%
Free cash flow$3.0M+1,296%

Valuation

See full
Market cap$694.58M-4.7%
Enterprise value$657.9M-8.0%
P/S5.9×-1.3×

Profitability

See full
Gross margin95.1%-1.1pp
Operating margin-0.1%-10.4pp
Net margin6.3%+3.3pp
FCF margin2.6%

Returns & leverage

See full
Return on equity8.2%+4.2pp
Debt / equity0.0×
Current ratio4.6×+1.0×

Where this comes from

Calculated from Gyre Therapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gyre Therapeutics, Inc.'s return on invested capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Gyre Therapeutics, Inc.'s return on invested capital?
Gyre Therapeutics, Inc. (GYRE) reported return on invested capital of -0.1% in Q1 2026.
How has Gyre Therapeutics, Inc.'s return on invested capital changed year-over-year?
Gyre Therapeutics, Inc.'s return on invested capital decreased by 100.6% year-over-year, from 19.3% to -0.1%.
What does return on invested capital mean?
Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.